Stock ARMP ARMATA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Delayed Nyse
Other stock markets
 02:45:14 2024-04-25 pm EDT 		5-day change 1st Jan Change
2.531 USD +1.23% Intraday chart for Armata Pharmaceuticals, Inc. -0.75% -21.89%
Mar. 21 Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M MT
Mar. 21 Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K
PU
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
MT
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
AQ
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
CI
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
AQ
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus
CI
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
AQ
Armata Pharmaceuticals, Inc. Announces CFO Changes
CI
Armata Pharmaceuticals, Inc. Announces Executive Changes
CI
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
AQ
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
AQ
Armata Pharmaceuticals, Inc. Announces That It Has Entered into A Credit and Security Agreement with Innoviva Strategic Opportunities Llc
CI
Armata Pharmaceuticals, Inc. Announces Executive Changes
CI
Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors
CI
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Microcap Value Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARMP Stock
  4. News Armata Pharmaceuticals, Inc.